Shanghai Junshi Bioscience Co., Ltd.: all 100 studies

Page 1 of 1. Open to participants first (20), then studies with results posted, then the rest; newest registration first within each.

• A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)Not yet recruitingNCT07876557Phase 2
• JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver CancerNot yet recruitingNCT07823348Phase 3
• A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT07808827Phase 3
• JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II StudyRecruitingNCT07518160Phase 2
• JS212 Combination Therapies in Metastatic Colorectal CancerRecruitingNCT07503756Phase 2
• A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07484724Phase 2
• Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid TumorsRecruitingNCT07480733Phase 2
• A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung CancerRecruitingNCT07309276Phase 2
• JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.RecruitingNCT07284134Phase 3
• JS207 Combination Therapy in Triple-negative Breast CancerRecruitingNCT07045311Phase 2
• JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06954467Phase 2
• A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid TumourRecruitingNCT06888830Phase 1/2
• A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal CancerRecruitingNCT06885385Phase 2
• Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI TherapyRecruitingNCT06868836Phase 2
• A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced MalignanciesRecruitingNCT06839105Phase 1
• A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)RecruitingNCT06170489Phase 3
• Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)RecruitingNCT06095583Phase 3
• A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of JS401RecruitingNCT06041165Phase 1
• Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed DyslipidemiaRecruitingNCT05621070Phase 3
• Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III StudyRecruitingNCT05342194Phase 3
• Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell CarcinomaCompletedNCT03829969Phase 3Results posted
• The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal CancerCompletedNCT03581786Phase 3Results posted
• JS203 Combination Regimens in B-Cell Non-Hodgkin's LymphomaActive, not recruitingNCT07081022Phase 2
• JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLCActive, not recruitingNCT06969027Phase 2
• JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLCActive, not recruitingNCT06944470Phase 2
• Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and ImmunotherapyTerminatedNCT06924606Phase 2
• A Bioequivalence Study of JS005 Pre-filled Syringe and JS005 Auto-injectorCompletedNCT06732973Phase 1
• Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid TumorsActive, not recruitingNCT06571422Phase 1
• JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）Active, not recruitingNCT06505837Phase 3
• A Clinical Study of JS005 in Patients With Ankylosing SpondylitisCompletedNCT06250062Phase 2
• A Clinical Trial Evaluated the Safety and Tolerability, Pharmacokinetic and Pharmacodynamics Profile, and Immunogenicity of a Single Dose of JS010 Injection in Healthy SubjectsCompletedNCT06158737Phase 1
• A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid TumorsCompletedNCT06139211Phase 1/2
• The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant TumorActive, not recruitingNCT06022250Phase 1
• A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT05975268Phase 3
• A Pharmacokinetic Study of JS002 in Healthy SubjectsCompletedNCT05859529Phase 1
• A Phase I Study Of JS015 in Patients With Advanced Solid TumorsCompletedNCT05770310Phase 1
• A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal CarcinomaCompletedNCT05751486Phase 1
• JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung CancerCompletedNCT05664971Phase 1/2
• A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic CancerTerminatedNCT05657418Phase 1
• A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced MalignanciesWithdrawnNCT05650203Phase 1
• Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's LymphomaActive, not recruitingNCT05618327Phase 1
• The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed HyperlipidemiaCompletedNCT05532800Phase 3
• A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid TumorsActive, not recruitingNCT05502393Phase 1
• A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid TumorsTerminatedNCT05427396Phase 1
• A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid TumorsTerminatedNCT05388279Phase 1
• Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple DosingCompletedNCT05344248Phase 1/2
• A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).CompletedNCT05325203Phase 3
• JS001+IMP4297 in Patients With Advanced CancerWithdrawnNCT05262842Phase 1
• A Clinical Study of TAB006 in Patients With Previously Treated, Advanced MalignanciesWithdrawnNCT05253105Phase 1
• Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpATerminatedNCT05242588Phase 2
• Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active ASCompletedNCT05212051Phase 2
• PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Phase 3
• A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19CompletedNCT05167279Phase 1
• A Study Explore JS001+JS002 in Patients With Advanced CancerTerminatedNCT05128539Phase 1
• The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced TumorCompletedNCT05061628Phase 1
• Clinical Study of JS007 in Patients With Advanced Solid TumorsStatus unknownNCT05049265Phase 1
• Study of JS004 Combined With Toripalimab for Advanced Lung CancerCompletedNCT05000684Phase 1/2
• Clinical Study of JS201 in Patients With Advanced Malignant TumorsStatus unknownNCT04956926Phase 1
• The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNCCompletedNCT04929080Phase 1/2
• A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell CancerCompletedNCT04856631Phase 1/2
• Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Phase 3
• Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer.TerminatedNCT04797702Phase 1/2
• The Safety and Efficacy of Multiple-dose of JS002 in Subject With HyperlipidemiaCompletedNCT04781114Phase 3
• JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection SubectsCompletedNCT04780321Phase 1/2
• A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid TumorsCompletedNCT04773951Phase 1
• Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Phase 3
• A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)CompletedNCT04605796Phase 2
• A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific MarkersTerminatedNCT04603040Phase 2
• A Phase I Study of JS108 in Patients With Advanced Solid TumorsTerminatedNCT04601285Phase 1
• A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial CarcinomaWithdrawnNCT04568304Phase 3
• Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCCActive, not recruitingNCT04523493Phase 3
• To Evaluate the Efficacy and Safety of JS002 in HoFH PatientsCompletedNCT04515927Phase 2
• A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of ChinaCompletedNCT04477772Phase 1
• A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia..CompletedNCT04469673Phase 1/2
• Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health SubjectsStatus unknownNCT04441918Phase 1
• Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell CancerCompletedNCT04394975Phase 3
• Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced MalignanciesCompletedNCT04278859Phase 1
• Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .Status unknownNCT04234620
• Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy VolunteersCompletedNCT04220073Phase 1
• A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health SubjectsCompletedNCT04197817Phase 1
• Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLCCompletedNCT04158440Phase 3
• Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic TreatmentCompletedNCT04085276Phase 3
• Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT04012606Phase 3
• Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKICompletedNCT03924050Phase 3
• Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular CarcinomaTerminatedNCT03867370Phase 1/2
• Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical ResectionActive, not recruitingNCT03859128Phase 2/3
• A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLCCompletedNCT03856411Phase 3
• A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI TreatmentCompletedNCT03513666Phase 2
• A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic MelanomaCompletedNCT03430297Phase 3
• Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant LymphomaCompletedNCT03316144Phase 1
• The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001CompletedNCT03301688Phase 1
• The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by SurgeryTerminatedNCT03178123Phase 2
• Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial CarcinomaStatus unknownNCT03113266Phase 2
• Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and MelanomaStatus unknownNCT03086174Phase 1
• Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic MelanomaStatus unknownNCT03013101Phase 2
• The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Phase 1/2
• Study of JS001 in Participants With Advanced Solid TumorsCompletedNCT02857166Phase 1
• Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast CancerCompletedNCT02838823Phase 1
• Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid TumorsStatus unknownNCT02836834Phase 1
• Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid TumorsCompletedNCT02836795Phase 1

← Shanghai Junshi Bioscience Co., Ltd. overview and focus areas